While serum CRP, IL-6, and SAA levels were not associated with increased risk of breast cancer recurrence in the HER2+ group, there was a strong association of the presence of a high-risk IL-6 promoter genotype with increased risk of HR+/HER2+ breast cancer relapse. Here, ERBB2 is linked to breast cancer.